|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: THY1 |
Gene summary for THY1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | THY1 | Gene ID | 7070 |
| Gene name | Thy-1 cell surface antigen | |
| Gene Alias | CD90 | |
| Cytomap | 11q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | B0YJA4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7070 | THY1 | AEH-subject1 | Human | Endometrium | AEH | 2.58e-26 | -6.71e-01 | -0.3059 |
| 7070 | THY1 | AEH-subject2 | Human | Endometrium | AEH | 2.21e-31 | -6.81e-01 | -0.2525 |
| 7070 | THY1 | AEH-subject3 | Human | Endometrium | AEH | 2.97e-23 | -6.09e-01 | -0.2576 |
| 7070 | THY1 | AEH-subject4 | Human | Endometrium | AEH | 6.10e-10 | -4.56e-01 | -0.2657 |
| 7070 | THY1 | AEH-subject5 | Human | Endometrium | AEH | 1.42e-31 | -6.69e-01 | -0.2953 |
| 7070 | THY1 | EEC-subject1 | Human | Endometrium | EEC | 2.81e-38 | -7.04e-01 | -0.2682 |
| 7070 | THY1 | EEC-subject2 | Human | Endometrium | EEC | 7.90e-36 | -6.97e-01 | -0.2607 |
| 7070 | THY1 | EEC-subject3 | Human | Endometrium | EEC | 5.88e-35 | -6.52e-01 | -0.2525 |
| 7070 | THY1 | EEC-subject4 | Human | Endometrium | EEC | 2.11e-27 | -6.57e-01 | -0.2571 |
| 7070 | THY1 | EEC-subject5 | Human | Endometrium | EEC | 4.66e-30 | -6.76e-01 | -0.249 |
| 7070 | THY1 | GSM5276934 | Human | Endometrium | EEC | 2.45e-28 | -6.49e-01 | -0.0913 |
| 7070 | THY1 | GSM5276935 | Human | Endometrium | EEC | 2.84e-37 | -7.03e-01 | -0.123 |
| 7070 | THY1 | GSM5276937 | Human | Endometrium | EEC | 2.30e-15 | -5.60e-01 | -0.0897 |
| 7070 | THY1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 3.44e-29 | -6.98e-01 | -0.1869 |
| 7070 | THY1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 6.29e-29 | -7.11e-01 | -0.1875 |
| 7070 | THY1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.64e-30 | -6.98e-01 | -0.1883 |
| 7070 | THY1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 2.08e-38 | -7.06e-01 | -0.1934 |
| 7070 | THY1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 3.43e-39 | -6.98e-01 | -0.1917 |
| 7070 | THY1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 6.07e-41 | -6.80e-01 | -0.1916 |
| 7070 | THY1 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 6.82e-15 | -5.39e-01 | -0.1269 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0033673111 | Thyroid | PTC | negative regulation of kinase activity | 115/5968 | 237/18723 | 5.98e-08 | 1.26e-06 | 115 |
| GO:0010975110 | Thyroid | PTC | regulation of neuron projection development | 194/5968 | 445/18723 | 1.05e-07 | 2.08e-06 | 194 |
| GO:004677716 | Thyroid | PTC | protein autophosphorylation | 110/5968 | 227/18723 | 1.25e-07 | 2.44e-06 | 110 |
| GO:000195220 | Thyroid | PTC | regulation of cell-matrix adhesion | 69/5968 | 128/18723 | 1.92e-07 | 3.51e-06 | 69 |
| GO:0051235112 | Thyroid | PTC | maintenance of location | 148/5968 | 327/18723 | 2.30e-07 | 4.07e-06 | 148 |
| GO:006156419 | Thyroid | PTC | axon development | 199/5968 | 467/18723 | 5.27e-07 | 8.53e-06 | 199 |
| GO:0010811112 | Thyroid | PTC | positive regulation of cell-substrate adhesion | 65/5968 | 123/18723 | 1.10e-06 | 1.62e-05 | 65 |
| GO:0034329111 | Thyroid | PTC | cell junction assembly | 180/5968 | 420/18723 | 1.17e-06 | 1.69e-05 | 180 |
| GO:000716020 | Thyroid | PTC | cell-matrix adhesion | 109/5968 | 233/18723 | 1.28e-06 | 1.84e-05 | 109 |
| GO:000740918 | Thyroid | PTC | axonogenesis | 178/5968 | 418/18723 | 2.17e-06 | 2.91e-05 | 178 |
| GO:0051651113 | Thyroid | PTC | maintenance of location in cell | 100/5968 | 214/18723 | 3.65e-06 | 4.67e-05 | 100 |
| GO:005076716 | Thyroid | PTC | regulation of neurogenesis | 156/5968 | 364/18723 | 5.86e-06 | 7.05e-05 | 156 |
| GO:015011717 | Thyroid | PTC | positive regulation of cell-substrate junction organization | 23/5968 | 33/18723 | 9.16e-06 | 1.04e-04 | 23 |
| GO:004308718 | Thyroid | PTC | regulation of GTPase activity | 148/5968 | 348/18723 | 1.63e-05 | 1.71e-04 | 148 |
| GO:00507708 | Thyroid | PTC | regulation of axonogenesis | 74/5968 | 154/18723 | 1.96e-05 | 2.00e-04 | 74 |
| GO:000722918 | Thyroid | PTC | integrin-mediated signaling pathway | 55/5968 | 107/18723 | 2.07e-05 | 2.08e-04 | 55 |
| GO:005189410 | Thyroid | PTC | positive regulation of focal adhesion assembly | 19/5968 | 28/18723 | 9.95e-05 | 8.15e-04 | 19 |
| GO:0045785112 | Thyroid | PTC | positive regulation of cell adhesion | 176/5968 | 437/18723 | 1.10e-04 | 8.83e-04 | 176 |
| GO:00313459 | Thyroid | PTC | negative regulation of cell projection organization | 83/5968 | 186/18723 | 1.72e-04 | 1.32e-03 | 83 |
| GO:00519608 | Thyroid | PTC | regulation of nervous system development | 177/5968 | 443/18723 | 1.72e-04 | 1.32e-03 | 177 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0467026 | Endometrium | AEH | Leukocyte transendothelial migration | 37/1197 | 114/8465 | 4.51e-07 | 6.11e-06 | 4.47e-06 | 37 |
| hsa04670111 | Endometrium | AEH | Leukocyte transendothelial migration | 37/1197 | 114/8465 | 4.51e-07 | 6.11e-06 | 4.47e-06 | 37 |
| hsa0467027 | Endometrium | EEC | Leukocyte transendothelial migration | 36/1237 | 114/8465 | 2.97e-06 | 3.91e-05 | 2.91e-05 | 36 |
| hsa0467036 | Endometrium | EEC | Leukocyte transendothelial migration | 36/1237 | 114/8465 | 2.97e-06 | 3.91e-05 | 2.91e-05 | 36 |
| hsa0467042 | Liver | HCC | Leukocyte transendothelial migration | 68/4020 | 114/8465 | 5.79e-03 | 1.64e-02 | 9.15e-03 | 68 |
| hsa0467052 | Liver | HCC | Leukocyte transendothelial migration | 68/4020 | 114/8465 | 5.79e-03 | 1.64e-02 | 9.15e-03 | 68 |
| hsa0467030 | Oral cavity | OSCC | Leukocyte transendothelial migration | 63/3704 | 114/8465 | 8.46e-03 | 1.96e-02 | 9.95e-03 | 63 |
| hsa04670113 | Oral cavity | OSCC | Leukocyte transendothelial migration | 63/3704 | 114/8465 | 8.46e-03 | 1.96e-02 | 9.95e-03 | 63 |
| hsa04670210 | Oral cavity | EOLP | Leukocyte transendothelial migration | 37/1218 | 114/8465 | 7.00e-07 | 6.85e-06 | 4.04e-06 | 37 |
| hsa0467038 | Oral cavity | EOLP | Leukocyte transendothelial migration | 37/1218 | 114/8465 | 7.00e-07 | 6.85e-06 | 4.04e-06 | 37 |
| hsa0467046 | Oral cavity | NEOLP | Leukocyte transendothelial migration | 31/1112 | 114/8465 | 4.39e-05 | 3.41e-04 | 2.14e-04 | 31 |
| hsa0467056 | Oral cavity | NEOLP | Leukocyte transendothelial migration | 31/1112 | 114/8465 | 4.39e-05 | 3.41e-04 | 2.14e-04 | 31 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| THY1 | ITGAM_ITGB2 | THY1_ITGAM_ITGB2 | THY1 | Breast | DCIS |
| THY1 | ITGAX_ITGB2 | THY1_ITGAX_ITGB2 | THY1 | Breast | DCIS |
| THY1 | ITGAM_ITGB2 | THY1_ITGAM_ITGB2 | THY1 | Breast | Healthy |
| THY1 | ITGAX_ITGB2 | THY1_ITGAX_ITGB2 | THY1 | Breast | Healthy |
| THY1 | ITGAM_ITGB2 | THY1_ITGAM_ITGB2 | THY1 | Breast | IDC |
| THY1 | ITGAX_ITGB2 | THY1_ITGAX_ITGB2 | THY1 | Breast | IDC |
| THY1 | ITGAM_ITGB2 | THY1_ITGAM_ITGB2 | THY1 | Cervix | ADJ |
| THY1 | ITGAX_ITGB2 | THY1_ITGAX_ITGB2 | THY1 | Cervix | ADJ |
| THY1 | ITGAX_ITGB2 | THY1_ITGAX_ITGB2 | THY1 | Cervix | Healthy |
| THY1 | ITGAM_ITGB2 | THY1_ITGAM_ITGB2 | THY1 | Cervix | Precancer |
| THY1 | ITGAX_ITGB2 | THY1_ITGAX_ITGB2 | THY1 | Cervix | Precancer |
| THY1 | ITGAX_ITGB2 | THY1_ITGAX_ITGB2 | THY1 | CRC | AD |
| THY1 | ITGAX_ITGB2 | THY1_ITGAX_ITGB2 | THY1 | CRC | ADJ |
| THY1 | ITGAM_ITGB2 | THY1_ITGAM_ITGB2 | THY1 | CRC | MSI-H |
| THY1 | ITGAX_ITGB2 | THY1_ITGAX_ITGB2 | THY1 | CRC | MSI-H |
| THY1 | ITGAX_ITGB2 | THY1_ITGAX_ITGB2 | THY1 | CRC | MSS |
| THY1 | ITGAM_ITGB2 | THY1_ITGAM_ITGB2 | THY1 | CRC | SER |
| THY1 | ITGAX_ITGB2 | THY1_ITGAX_ITGB2 | THY1 | CRC | SER |
| THY1 | ITGAM_ITGB2 | THY1_ITGAM_ITGB2 | THY1 | Endometrium | ADJ |
| THY1 | ITGAX_ITGB2 | THY1_ITGAX_ITGB2 | THY1 | Endometrium | ADJ |
| Page: 1 2 3 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| THY1 | SNV | Missense_Mutation | rs147718110 | c.380T>G | p.Leu127Arg | p.L127R | P04216 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C5-A1M9-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| THY1 | SNV | Missense_Mutation | novel | c.5N>G | p.Asn2Ser | p.N2S | P04216 | protein_coding | deleterious(0.01) | benign(0.025) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| THY1 | SNV | Missense_Mutation | c.258G>T | p.Met86Ile | p.M86I | P04216 | protein_coding | tolerated(0.7) | benign(0) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| THY1 | SNV | Missense_Mutation | novel | c.187N>A | p.Leu63Ile | p.L63I | P04216 | protein_coding | tolerated(0.65) | benign(0.03) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| THY1 | SNV | Missense_Mutation | rs533696940 | c.467N>T | p.Thr156Met | p.T156M | P04216 | protein_coding | tolerated(0.15) | benign(0.003) | TCGA-BK-A13B-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| THY1 | SNV | Missense_Mutation | novel | c.23N>T | p.Ala8Val | p.A8V | P04216 | protein_coding | tolerated(0.23) | benign(0.003) | TCGA-WQ-A9G7-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| THY1 | SNV | Missense_Mutation | c.340N>G | p.Pro114Ala | p.P114A | P04216 | protein_coding | tolerated(0.77) | benign(0.001) | TCGA-50-5930-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxotere | PD | |
| THY1 | SNV | Missense_Mutation | c.128N>T | p.Thr43Ile | p.T43I | P04216 | protein_coding | deleterious(0.02) | benign(0.089) | TCGA-55-7903-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| THY1 | SNV | Missense_Mutation | c.29N>A | p.Leu10Gln | p.L10Q | P04216 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-69-7979-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| THY1 | SNV | Missense_Mutation | c.277N>T | p.Ala93Ser | p.A93S | P04216 | protein_coding | tolerated(0.72) | benign(0.003) | TCGA-86-8054-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | paclitaxel | CR |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7070 | THY1 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | HEL | 6186895 | ||
| 7070 | THY1 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | THYMOSIN FRACTION 5 | 6141799 | ||
| 7070 | THY1 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | FCA | 9521021 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |